These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 34403220)

  • 1. Targeting myeloid-derived suppressor cells for cancer therapy.
    Tang H; Li H; Sun Z
    Cancer Biol Med; 2021 Aug; 18(4):992-1009. PubMed ID: 34403220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy.
    Li X; Zhong J; Deng X; Guo X; Lu Y; Lin J; Huang X; Wang C
    Front Immunol; 2021; 12():754196. PubMed ID: 35003065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of targeting MDSCs in tumor microenvironment.
    Sui H; Dongye S; Liu X; Xu X; Wang L; Jin CQ; Yao M; Gong Z; Jiang D; Zhang K; Liu Y; Liu H; Jiang G; Su Y
    Front Immunol; 2022; 13():990463. PubMed ID: 36131911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
    Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G
    J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
    Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects.
    Li T; Liu T; Zhu W; Xie S; Zhao Z; Feng B; Guo H; Yang R
    Clin Med Insights Oncol; 2021; 15():11795549211035540. PubMed ID: 34408525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing immune checkpoint blockade therapy of genitourinary malignancies by co-targeting PMN-MDSCs.
    Lu X; Lu X
    Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188702. PubMed ID: 35227829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives.
    Lu LC; Chang CJ; Hsu CH
    J Hepatocell Carcinoma; 2019; 6():71-84. PubMed ID: 31123667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid-derived suppressor cells in head and neck squamous cell carcinoma.
    He JY; Huo FY; Tang HC; Liu B; Bu LL
    Int Rev Cell Mol Biol; 2023; 375():33-92. PubMed ID: 36967154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target.
    Ozbay Kurt FG; Lasser S; Arkhypov I; Utikal J; Umansky V
    J Clin Invest; 2023 Jul; 133(13):. PubMed ID: 37395271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen-like protein 2 promotes tumor immune suppression by regulating cholesterol metabolism in myeloid-derived suppressor cells.
    Wu L; Liu X; Lei J; Zhang N; Zhao H; Zhang J; Deng H; Li Y
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
    De Cicco P; Ercolano G; Ianaro A
    Front Immunol; 2020; 11():1680. PubMed ID: 32849585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting PIM1-Mediated Metabolism in Myeloid Suppressor Cells to Treat Cancer.
    Xin G; Chen Y; Topchyan P; Kasmani MY; Burns R; Volberding PJ; Wu X; Cohn A; Chen Y; Lin CW; Ho PC; Silverstein R; Dwinell MB; Cui W
    Cancer Immunol Res; 2021 Apr; 9(4):454-469. PubMed ID: 33579728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging role of myeloid-derived suppressor cells in radiotherapy.
    Kang C; Jeong SY; Song SY; Choi EK
    Radiat Oncol J; 2020 Mar; 38(1):1-10. PubMed ID: 32229803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.
    Gaißler A; Bochem J; Spreuer J; Ottmann S; Martens A; Amaral T; Wagner NB; Claassen M; Meier F; Terheyden P; Garbe C; Eigentler T; Weide B; Pawelec G; Wistuba-Hamprecht K
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
    Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified method for differentiation of myeloid-derived suppressor cells
    Zhou H; Xie Z; Morikawa N; Sakurai F; Mizuguchi H; Okuzaki D; Okada N; Tachibana M
    Biochem Biophys Rep; 2023 Mar; 33():101416. PubMed ID: 36605123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma.
    Loeuillard E; Yang J; Buckarma E; Wang J; Liu Y; Conboy C; Pavelko KD; Li Y; O'Brien D; Wang C; Graham RP; Smoot RL; Dong H; Ilyas S
    J Clin Invest; 2020 Oct; 130(10):5380-5396. PubMed ID: 32663198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.